Lum T - Search Results

1

Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.

Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, Shin JS, O'Toole S, Anderson L, Scolyer RA, Gupta R. Paver EC, et al. Among authors: lum t. Pathology. 2021 Feb;53(2):141-156. doi: 10.1016/j.pathol.2020.10.007. Epub 2020 Dec 30. Pathology. 2021. PMID: 33388161 Review.

2

Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.

Satgunaseelan L, Gupta R, Madore J, Chia N, Lum T, Palme CE, Boyer M, Scolyer RA, Clark JR. Satgunaseelan L, et al. Among authors: lum t. Pathology. 2016 Oct;48(6):574-80. doi: 10.1016/j.pathol.2016.07.003. Epub 2016 Aug 30. Pathology. 2016. PMID: 27590194

3

PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.

Roper E, Lum T, Palme CE, Ashford B, Ch'ng S, Ranson M, Boyer M, Clark J, Gupta R. Roper E, et al. Among authors: lum t. Pathology. 2017 Aug;49(5):499-505. doi: 10.1016/j.pathol.2017.04.004. Epub 2017 Jun 27. Pathology. 2017. PMID: 28666643

4

Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status.

Holmes M, Mahar A, Lum T, Kao S, Cooper WA. Holmes M, et al. Among authors: lum t. J Clin Pathol. 2021 Feb;74(2):123-128. doi: 10.1136/jclinpath-2020-206709. Epub 2020 Jun 23. J Clin Pathol. 2021. PMID: 32576631

5

EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.

Cooper WA, Yu B, Yip PY, Ng CC, Lum T, Farzin M, Trent RJ, Mercorella B, Clarkson A, Kohonen-Corish MR, Horvath LG, Kench JG, McCaughan B, Gill AJ, O'Toole SA. Cooper WA, et al. Among authors: lum t. J Clin Pathol. 2013 Sep;66(9):744-8. doi: 10.1136/jclinpath-2013-201607. Epub 2013 Jun 11. J Clin Pathol. 2013. PMID: 23757037

6

Molecular assays in breast cancer pathology.

O'Toole SA, Selinger CI, Millar EK, Lum T, Beith JM. O'Toole SA, et al. Among authors: lum t. Pathology. 2011 Feb;43(2):116-27. doi: 10.1097/PAT.0b013e3283430926. Pathology. 2011. PMID: 21233672 Review.

7

Intrapatient homogeneity of BRAFV600E expression in melanoma.

Menzies AM, Lum T, Wilmott JS, Hyman J, Kefford RF, Thompson JF, O'Toole S, Long GV, Scolyer RA. Menzies AM, et al. Among authors: lum t. Am J Surg Pathol. 2014 Mar;38(3):377-82. doi: 10.1097/PAS.0000000000000136. Am J Surg Pathol. 2014. PMID: 24335665

8

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

Kakavand H, Crainic O, Lum T, O'Toole SA, Kefford RF, Thompson JF, Wilmott JS, Long GV, Scolyer RA. Kakavand H, et al. Among authors: lum t. Pathology. 2014 Apr;46(3):193-8. doi: 10.1097/PAT.0000000000000077. Pathology. 2014. PMID: 24614711

9

Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics.

Luk PP, Selinger CI, Eviston TJ, Lum T, Yu B, O'Toole SA, Clark JR, Gupta R. Luk PP, et al. Among authors: lum t. Pathology. 2015 Dec;47(7):659-66. doi: 10.1097/PAT.0000000000000322. Pathology. 2015. PMID: 26517645

10

Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.

Busam KJ, Vilain RE, Lum T, Busam JA, Hollmann TJ, Saw RP, Coit DC, Scolyer RA, Wiesner T. Busam KJ, et al. Among authors: lum t. Am J Surg Pathol. 2016 Jun;40(6):786-95. doi: 10.1097/PAS.0000000000000611. Am J Surg Pathol. 2016. PMID: 26872010 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page